TreatSMA community shows amazing generosity

Recently, acting as part of TreatSMA, Gary McKie (trustee) asked the community if anyone had a panthera chair that a young North East family could loan, to keep their sons arm strength up, as his consultant had recommended sourcing a manual chair.

We would like to thank the community once again for their amazing response. We managed to source not one, but two chairs, a Panthera micro and bambino, 2 of the lightest manual chairs in the world. We would like to personally thank the 2 families who have contributed towards our appeal.

We have today, delivered the micro to young Rayne (left), who is 2 years old and type 2. This will help him to keep his upper body strength and also to gain strength once he starts treatment in the coming months. He was straight into the chair exploring his surroundings, and as you can see his beaming smile says it all.

The other chair which is the Panthera Bambino, will be used by 7 year old Sam Mckie. Sam is a week type 2, but is still able to propel this chair due to its lightweight frame. We hope that when Sam starts treatment in the coming months the exercise that he gets from using this chair will help build on what Spinraza can do for him.

The Bambino has very kindly been donated to TreatSMA to loan out to families who may need equipment unavailable to them elsewhere. As mentioned previously, it will be in use for a while to come, but as and when it becomes available, we will inform the community, and accept enquiries for its use.

Thank you once again to you, the community.

Latest Posts

  • Calling on all the community to ACT NOW to avoid losing treatments!

    Calling on all the community to ACT NOW to avoid losing treatments!

    Currently, there are two approved treatments for SMA: risdiplam and nusinersen. These treatments were initially approved temporarily under Managed Access Agreements while the NHS and NICE gathered data to assess their cost-effectiveness. Now, as these agreements come to an end, both treatments face a crucial review.

    Read more

  • NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam

    SMA UK are proud to join together with Treat SMA and MDUK to bring you this webinar about NICE’s upcoming Multi Technology Assessment for Spinraza and Risdiplam. 2024 sees the end of the managed access agreements (MAAs) for the two treatments. An expert committee will gather to assess the new clinical and real-world evidence, along…

    Read more

  • Let the battle begin

    Let the battle begin

    This year the Managed Access Agreement for Spinraza and Risdiplam expires. The MAA was put in place five years ago so the pharmaceutical companies could gather more evidence to resubmit to NICE for approval on the NHS with Biogen extending their MAA by a year.

    Read more